In a mouse disease model for early-onset AD, delivering a specific AAV-siRNA against Acat1 by direct injection into mouse hippocampus significantly reduced ACAT1 enzyme activity in the brain and reduced amyloidopathy [40]. The gene discussed is ACAT1; the disease is Alzheimer disease.